TABLE 1.
Summary of evidence demonstrating changes in circulating cell-free mitochondrial DNA in human pregnancy complications
| Pregnancy Complication/ccf-mtDNA Compared with Healthy Pregnancy | Gestational Age at Sample | Blood Component | Reference |
|---|---|---|---|
| Preeclampsia | |||
| Increased | Term/delivery | Whole blood | Qiu et al. (89) |
| Decreased | First trimester | Whole blood | Busnelli et al. (97) |
| Increased | 37–40 wk | Plasma | McCarthy and Lenny (90) |
| Greater increase from 15 to 20 wk | 15–20 wk | Plasma | Williamson et al. (20) |
| Increased | 30–31 wk | Serum | Marschalek et al. (98) |
| Increased | 34–39 wk | Serum | Ozeki et al. (18) |
| Placental abruption | |||
| No significant difference | 35–38 wk | Whole blood | Williams et al. (19) |
| IUGR | |||
| Increased | Third trimester | Whole blood | Colleoni et al. (16) |
| GDM | |||
| Increased | 19–21 wk | Plasma | McElwain and McCarthy (92) |
ccf-mtDNA, circulating cell-free mitochondrial DNA; IUGR, intrauterine growth restriction; GDM, gestational diabetes mellitus.